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Abstract
The physiological functions of PrPC remain enigmatic, but the central domain, comprising highly conserved regions of the
protein may play an important role. Indeed, a large number of studies indicate that synthetic peptides containing residues
106–126 (CR) located in the central domain (CD, 95–133) of PrPC are neurotoxic. The central domain comprises two
chemically distinct subdomains, the charge cluster (CC, 95–110) and a hydrophobic region (HR, 112–133). The aim of the
present study was to establish the individual cytotoxicity of CC, HR and CD. Our results show that only the CD peptide is
neurotoxic. Biochemical, Transmission Electron Microscopy and Atomic Force Microscopy experiments demonstrated that
the CD peptide is able to activate caspase-3 and disrupt the cell membrane, leading to cell death.
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Introduction
PrPC is an endogenous GPI-anchored protein that is highly
expressed in some neuronal and glial populations of the
telencephalon (e.g., [1,2,3]). The N-terminal tail of PrPC contains
a signal sequence that promotes its intracellular trafficking to the
Golgi network (e.g., [4]), an octarepeat region (OR) and a central
domain (CD) (e.g., [5,6]). The CD (residues 95–133) comprises
two regions: the charged cluster (CC, residues 95–110) and the
hydrophobic core (HR, residues 112–133), which makes up the
first transmembrane domain (TM1) of PrPC [7,8]. Conversion of
PrPC to the b-sheet-enriched PrPSC is responsible for prion
pathology in transmissible spongiform diseases. Although the
mechanisms that mediate this conformational change remain
elusive (e.g., [9,10]), it seems that some residues located in the HR
are directly implicated in this process (e.g., [11]). In fact, based on
the pioneering study of Forloni and coworkers [12], several
researchers have used a synthetic PrPC fragment of 21 residues of
the CD domain (PrP106–126) as a model of prion neurotoxicity (e.g.,
[13,14]), glial activation (e.g., [15,16]) or phagocyte activation
(e.g., [17]). However, the reported toxic properties of this peptide
and the participation of the endogenous PrPC in neurotoxicity
differ between studies (e.g., [18,19,20,21,22,23]). From a mech-
anistic point of view, some studies have reported that membrane
modifications or the putative endocytosis of PrP106–126 mediate its
neurotoxic effects [24,25] in contrast to others [26], although it has
also been reported that the peptide is able to modify membrane
viscosity properties [27]. This is important if we take into account
that membrane binding of PrPC is required to induce neurotox-
icity [28] (see [6,29] for a review).
In the healthy nervous system non-amyloidogenic processing of
proteins (e.g., amyloid precursor protein, APP) plays an important
role in neuronal physiology (e.g., sAPPa as neurotrophin or long-
term potentiation) [30,31].
In fact, healthy PrPC has been implicated in neurite extension
and cell proliferation [32]. However, abnormal processing of these
proteins leading to intermediate conformations of the protein (e.g.,
APP or PrPC) has been reported to produce cytotoxic species
rather that the fibrillar amyloidogenic form (e.g., [23,33]). Studies
using chemically modified PrP106–126 have provided data on the
physicochemical aspects of peptide toxicity in vitro [34,35],
supporting the idea that amyloid fibrils may not be the neurotoxic
form of the prion (e.g., [36]). Indeed, the small oligomeric PrP
species associated with the HR domain has been reported to be
responsible for the highly characteristic thalamic pathology in
Creutzfeldt-Jakob disease (CJD) [37].
In the present study, we used the full-length mouse CD peptide
(residues 95–133) and its component regions CC and HR to
determine participation in the neurodegenerative process associ-
ated with the CD. We show that the CD peptide, although not
being refolded in a fibrillar manner, induces neuronal toxicity
similar to that of PrP106–126. Surprisingly, electron microscopy
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revealed that the CD fragment presents protofibrillar structures in
physiological solution, leading to progressive disorganization of
phosphatidyl choline membranes as seen in atomic force
microscopy, and promoting cell death independently of PrPC
expression in cultured cells. Despite the large number of studies
reporting the neurotoxicity of different prion peptides, we indicate
that the synthetic peptide comprising the CD domain is highly
neurotoxic due to its inability to transform protofibrillar structures
to mature fibrils.
Materials and Methods
Ethics Statement
All experimental procedures were performed in accordance
with the guidelines of the Spanish Ministry of Science and
Technology, following European Standards. The Animal Exper-
imentation Ethics Committee (CEEA) of the University of
Barcelona approved this study (document file number 115/11).
Pregnant mice were sacrificed by cervical dislocation before
removing the embryos. Prenatal and neonatal mice were
euthanized by decapitation.
Peptide Synthesis
Peptides mimicking the CC and HR (residues 95–110 and 112–
133, respectively) of PrPC were synthesized by Invitrogen
(Carlsbad, USA, CA), and peptide PrP106–126 was purchased from
Sigma Aldrich (Andover, UK). The CD-mimicking peptide
(residues 95–133) was synthesized by the Combinatorial Chem-
istry Unit (UQC) of the Scientific Park of Barcelona (Barcelona,
Spain) using ChemmatrixTM-based (Matrix-InnovationTM, Mon-
treal, Quebec, Canada) solid phase synthesis.
The CD was synthesized on an Aminomethyl–ChemMatrixTM
PEG resin [38] (Aminomethyl CM resin, 0.17 mmol, 0.62 mmol/
g) and was washed before use as follows: MeOH (261 min), DMF
(261 min), CH2Cl2 (361 min), TFA-CH2Cl2 (1:99) (361 min),
DIEA-CH2Cl2 (1:19) (361 min) and CH2Cl2 (361 min). The AB
linker (3-(4-hydroxymethylphenoxy) propionic acid) was incorpo-
rated with HATU-HOAt-DIEA (3:3:3:9). The first amino acid
(Fmoc-Ser(OtBu)-OH) was introduced manually using DIPCDI:-
HOAt:DMAP (10:10:10:0.1) for 90 min, followed by an acetyla-
tion step. After elimination of the Fmoc group with piperidi-
ne:DMF (1:1, 20 min), elongation of the peptide was continued
automatically on an ABI 433 A peptide synthesizer (Applied
Biosystems, Foster City) using standard Fmoc chemistry and the
FastMoc protocol using Fmoc-aa-HATU-HOAt-DIEA
(10:10:10:30) as the coupling system. Cleavage was performed
Figure 1. HPLC traces at 220 nm of CC, HR, CD and PrP106-126 peptides. HPLC conditions: Symmetry 300
TM C4 column (4.66250 mm, 5 mm)
with a non-linear gradient of 0.1% aqueous TFA/0.1% TFA in CH3CN, from 95:5 to 15:85 over 5 min and 15:85 to 40:60 in 15 min at 60uC, flow rate of
1 mL/min. Note that the impurities are principally glycine deletions and are found in all four peptides. The extraordinary hydrophobic properties of
the HR peptide in contrast with CC should be noted. The CD peptide clearly shows a mixture of biochemical properties of the HR and CC forms.
doi:10.1371/journal.pone.0070881.g001
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using TFA-TIS-EDT: H2O (94:1:2.5:2.5) for 90 min and the
crude peptide was lyophilized under non-oxidative conditions.
After lyophilisation, a disaggregating protocol [39] was applied.
This protocol consisted of dissolving the crude peptide in hot TFA,
removing the acid by evaporation, and dissolving the residue in
HFIP. The crude peptide was characterized by analytical HPLC
(30%) and MALDI-TOF (m/z calcd. 3977.6; m/z observed
3978.83 [M+H]+).
CD peptide purification was performed using an HPLC-MS
semi-preparative system (Waters, Milford MA) with a reverse-
phase Symmetry C8 column (306100 mm, 5 mm) using a non-
linear gradient (from 5 to 15% in 5 min and 15 to 35% in 20 min)
of CH3CN (containing 0.1% TFA) and H2O (containing 0.1%
TFA). Peptide detection was carried out via MS and UV
absorption at 220 nm. Characterization of the final CD peptide
was carried out by HPLC (tr=10.7 min; 51%), HPLC-MS (m/z
calcd. 3977.6; observed 1989.83 [M+2H]+/2, 1326.63 [M+3H]+/
3, 995.26 [M+4H]+/4, 796.35 [M+5H]+/5, 663.86 [M+6H]+/6)
and MALDI-TOF (m/z calcd. 3977.6; observed 3976.02
[M+H]+).
Transmission Electron Microscopy (TEM) Procedures
Lyophilized peptides were dissolved directly in 0.1 M phosphate
buffered saline (PBS) pH 7.4 (CC, CD) or in DMSO 98% (10X
stock solution) and then 0.1 M PBS (HR), to obtain the
appropriate concentrations (50–100 mM) for further experiments.
For TEM, peptide solutions were fixed to Carbon-Forward-coated
copper supports. After 0, 24 or 48 hours, negative staining was
performed using a 2% PTA-based (phosphotungstic acid) stain
(pH 7.4), after which samples were placed in silica-based desiccant
for a minimum of 2 hours. Finally, we proceeded to TEM
observation using a Leica microscope (Wetzlar, Germany) at the
Electron Microscopy Service, University of Barcelona, Barcelona,
Spain.
Thioflavine T (ThT) Amyloidal Quantification Assay
ThT stock solution was prepared at 2.5 mM (dissolved in
10 mM phosphate buffer (potassium), 150 mM NaCl, pH 7.0) and
preserved in single-aliquot form at 280uC. The ThT assay was
performed by dissolving 50 mg of lyophilized peptide sample in
1 ml of freshly prepared ThT (final concentration 62.5 mM)
followed by quantification using an absorbance/excitation spec-
trofluorometer LS-55 (Perkin-Elmer, Waltham, USA, MA). A
peptide-free blank solution was used to measure residual ThT
fluorescence. Non-refracting quartz cells (Hamamatsu Photonics,
Hamamatsu, Japan) with a self-agitation system were employed to
avoid fluorescence disturbance during experiments.
Primary Neuronal Cultures and Peptide Treatments
Prnp knockout Zu¨rich I mice (Prnp0/0) were purchased from the
European Mouse Mutant Archive (EMMA, Monterotondo, Italy).
Prnp0/0 mice were backcrossed with C57BL6J mice for at least 10
generations to obtain 92–95% of the C57BL6J microsatellite
markers (Charles River background analysis service), compared
with the 46–48% found in Zu¨rich I mice with a C57BL6J/129Sv
mixed background [40]. Primary cortical cultures were prepared
from E15.5–16.5 mouse embryo brains from heterozygous Prnp+/0
parents as previously described (e.g. [19]). Briefly, cortical regions
were isolated, trypsinized and treated with DNAse. After counting,
healthy cells from each genotype were cultured in six-well culture
plates (300,000 cells/well, 35 mm ø). Culture plates were from
Nunc (Denmark), and culture media and supplements from
Invitrogen (Carlsbad, USA, CA). After 5–7 days in vitro (DIV) and
genotypic identification by PCR on tail-derived DNA, peptides
were added to the culture media (see below).
Cerebellar granule neuron (CGN) cultures were prepared from
5-day-old pups (Prnp0/0 and Prnp+/+ genotypes) as described
previously (e.g., [41]). Isolating and dissecting procedures, as well
as culture media, were as described previously [42]. CGN were
cultured at 120,000 cells per well (12-well plate, 12 mm ø
coverslips) for 5 days prior to further treatment with peptides.
Peptides were prepared as above and added to the cell cultures
immediately after resuspension (or allowed to aggregate at room
temperature for 24 h when required). The peptides were added to
the culture media at concentrations ranging from 5 to 80 mM. In
the case of HR peptide, the concentration of DMSO in the cell
cultures was always below 0.5%.
Cell Viability and Immunological Methods
Cell viability was assessed using a slightly modified propidium
iodide (PI) uptake method, as described by Enguita et al. [43].
Propidium iodide fluorescence was measured in 24-well plates
using an Infinite M200 PRO scanner (TECAN Group, Ma¨nne-
dorf, Switzeland) with 530-nm excitation (25-nm band pass) and
645-nm (40-nm band pass) emission filters. Baseline fluorescence
F1 was measured 1 h after addition of propidium iodide (30 mM)
as an index of cell death not related to the treatment.
Subsequently, fluorescence readings were taken at different times
after the onset of the treatment. At the end of the experiment, the
cells were permeabilized for 10 min with 500 mM digitonin at
37uC to obtain the maximum fluorescence corresponding to 100%
of cell death (Fmax). The percentage of cell death was calculated as
follows: % cell death = 1006(Fn–F1)/(Fmax–F1), where Fn is the
fluorescence at any given time. Cells were kept in the incubator
between measurements.
In parallel, peptide-treated cells were scraped off in lysis buffer
containing 1X protease inhibitor cocktail. Cell extracts were boiled
in Laemmli sample buffer at 100uC for 5 min, followed by 10%
SDS–PAGE electrophoresis, and then electrotransferred to
nitrocellulose membranes for 6 h at 4uC, and processed for
Western blotting using primary antibodies and detected by
enhanced chemilluminescence using the ECL-plus kit from
Amersham-Pharmacia Biotech, UK. Each nitrocellulose mem-
brane was used to detect both protein levels of tubulin (Sigma
Aldrich, Andover, UK) and cleaved caspase-3 (Cell Signaling,
Beverly, MA, USA).
For immunochemistry, cells were fixed with 0.1 M phosphate
buffered 4% paraformaldehyde (pH 7.4). a-Cleaved caspase-3 and
a-neuronal-specific bIII-tubulin isoform (TUJ-1, Millipore) anti-
bodies were employed to identify degenerating neurons. After
mounting on FluoromountTM (Vector Labs, Burlingame, USA),
labelled cells were photodocumented using an Olympus BX61
fluorescence microscope equipped with a DX72 cooled camera.
For quantification, the relative percentage of caspase-3-positive
cells compared to TUJ-1-positive neurons was determined using
Quantity One Image Software Analysis (Bio-Rad, Hercules, CA,
USA).
Atomic Force Microscopy (AFM) Procedures
Chloroform/methanol (50:50 (v/v)) stock solutions containing
appropriate amounts of 1,2-Dimyristoyl-sn-glycero-3-phosphocho-
line (DMPC) were dried under a stream of oxygen-free N2. The
resulting thin lipid film was then kept under high vacuum for
several hours to ensure the absence of organic solvent traces.
DMPC vesicles were obtained by hydration in an excess of
resuspension buffer (RB) (10 mM Hepes, 150 mM NaCl, 20 mM
CaCl2; pH 7.4). The spread of the planar lipidic membranes on
Central Domain Peptide of Cellular Prion Protein
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mica was obtained using the vesicle fusion technique [44]. Briefly,
aliquots (60 mL) of DMPC liposomes were pipetted onto freshly
cleaved green mica muscovita, allowed to stabilize at 25uC (above the
transition temperature of the phospholipid mixture) for 15 min,
and then rinsed with imaging buffer (10 mM Hepes, 150 mM
NaCl; pH 7.4). The probe was immediately immersed in the
buffer. For all such experiments it was necessary to drift equilibrate
and thermally stabilize the cantilever.
Figure 2. Kinetics of aggregation study of CC, HR, CD and PrP106–126 peptides through TEM and ThT fluorescence curves. A–L) TEM of
the four peptides at 0, 24 and 48 hours post-dissolution. The HR peptide contains higher amounts of amyloid fibrils (A, E, I) than CC at all points (B, F,
J). Note the progressive decrease in number of spherical structures over time in the CD peptide (C, G, K) and the coexistence of spherical and
protofibrillar structures in the PrP106–126 peptide samples (D, H, L). Scale bars: A = 200 nm pertains to D–I, K–L; B = 500 nm pertains to C, J. M–P) TEM
higher magnification of the four peptides just after dissolution. M) High TEM magnification of an amyloid fibril of HR peptide (black arrows). N) CC
sample showing presence of no amyloid structure. O) High TEM magnification of spherical structures (black arrowhead). Black arrows indicate the
presence of presumably intermediate or forming amyloid fibrils. P) PrP106–126 sample showing very small spherical structures together with
protofibrillar aggregates. Scale Bars: M= 200 nm; N= 1 mm; O= 500 nm; P = 200 nm. Q) ThT assay showing ability of HR to form amyloidal structures.
50 mg of each lyophilized peptide sample were resuspended in 1 ml of freshly prepared ThT 62.5 mM. Note the strong increase in HR-derived
fluorescence emission at 8 hours post-dissolution (,36106 fluorescence relative units), and the progressive decrease up to 48 hours. The CD, CC and
PrP106–126 peptides do not show any fluorescence peak over time. Three independent experiments were carried out with the three batches of each
peptide, showing equal proportional results. The results presented correspond to the mean 6 SEM of these independent assays.
doi:10.1371/journal.pone.0070881.g002
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Peptide samples were prepared as described for culture/
transmission electron microscopy. After resuspension, the peptide
sample was injected into the AFM cell, and images were recorded
in tapping mode with a commercial Digital Instruments (Santa
Barbara, CA, USA) Nanoscope III AFM fitted with a 15 mm
scanner (d-scanner). Standard Si3N4 tips, with a nominal force
constant of 0.1 N/m (Digital Instruments), were used. Images
were flattened using Nanoscope III software. The lipid-to-protein
ratio (w/w, LPR) found to be appropriate for the performance of
the experiments was 27:0.5.
SUVs Preparation and Permeability Assay of the Lipid
Vesicles
The lipid was dissolved in chloroform/methanol (2:1, v/v) and
dried under a stream of oxygen-free N2. Lipidic vesicles were
obtained by hydration of the resulting thin lipid film in 400 ml of a
mixed solution of 12.5 mM ANTS, 45 mM DPX, 50 mMHEPES
(pH 7.4) and 20 mM NaCl at a concentration of 1.0 mg/ml.
Small unilamellar vesicles (SUVs) were prepared by sonication and
the vesicles were added onto HiTrapTM (GE Healthcare,
Buckinghamshire, UK) desalting column and eluted to 100 mM
with 50 mM HEPES, 100 mM NaCl, pH 7,4. After 20 min of
each peptide treatment, the fluorescence intensities were recorded
with 355-nm excitation and 512-nm emission filters (Infinite M200
PRO scanner (TECAN Group, Ma¨nnedorf, Switzeland)). The
fluorescence intensity corresponding to 100% leakage was
determined by adding Triton X-100 (2.5%, v/v) into the vesicles
until the maximum intensity achieved [45].
Statistical Analysis
All results are shown as mean 6 SEM. One-way analysis of
variance was used for statistical analysis of data using Statgraphics
plus for Windows software version 5.1 (Statpint Technologies Inc.,
Warrenton, VA, USA). p,0.01 or p,0.05 were considered
statistically significant.
Figure 3. CD peptide induces apoptotic cell death independently of PrPC expression. A) PI histogram showing the percentage of non-
viable cortical neurons over time after stimulation with the peptides (40 mM) immediately after dissolution. Note the cytotoxicity exerted by CD
peptide, in contrast to CC, HR, and PrP106–126, which are innocuous in the same conditions. B) The same PI histogram after stimulation with the
peptides left to aggregate for 24 h. In this case only PrP106–126 shows relevant cytotoxicity. C) Dose-dependent cell death induced over time by freshly
diluted CD peptide in cultured cortical neurons. Bars represent the mean 6 SEM of three independent experiments (* p,0.05, ** p,0.01, vs vehicle-
treated cells). D) Western blot showing the cleavage of caspase-3 induced by the 40 mM CD peptide. Tubulin was used as the loading control. E)
Cleaved caspase-3 staining indicating apoptotic cell death induced by the CD peptide. Tuj1 (a-neuronal-specific bIII-tubulin isoform) was used as a
marker for neurons. Note the independence from PrPC expression.
doi:10.1371/journal.pone.0070881.g003
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Results
Characterization of the Peptides used in the Present
Study
In order to decrease variability between peptide samples, three
batches (#1, #2 and #3) of each peptide were purchased from
Invitrogen or Sigma Aldrich or synthesized by UQC (see Materials
and Methods section for details). Subsequently all peptides,
regardless of their origin, were analysed via mass spectrometry
prior to their use in the UQC. In terms of the quality of the
fragment, the CC, HR and CD peptides presented similar profiles
(Figure 1). Sample impurities likely corresponded to glycine-
related deletions characteristic of the synthesis procedure, with
similar levels observed in the three peptides. All batches presented
equivalent mass spectra, showing no incongruence in terms of
toxicity or aggregation. The results shown in Figure 1 were
obtained using batch #2.
TEM Analysis of Aggregative Properties of Peptides
In order to determine the aggregation kinetics of the synthesized
peptides, TEM observations were performed at 100 mM of each
peptide. As illustrated in Figure 2, TEM micrographs revealed the
lack of fibrils in CC samples (Figures 2B, 2F and 2J). In contrast,
TEM analysis of freshly prepared HR peptide samples showed the
extensive presence of amyloid fibrils immediately after preparation
(Figures 2A, 2E, and 2I), suggesting that this peptide might be
already aggregated in the lyophilized state. In the case of PrP106–
126 the micrographies initially showed very small spherical
material together with some aggregates. After 24 h or 48 h of
aggregation we observed some protofibrils and fibrils together with
larger spherical structures. (Figures 2D, 2H and 2L). Surprisingly,
we observed the presence of non-fibrillar structures in the substrate
of the TEM sample corresponding to the CD peptide just after
dissolution. The amount of these species decreased over time,
suggesting the inability of this peptide to form mature fibrils
(Figures 2C, 2G, and 2K). Higher magnification of these regions
revealed the presence of round non-fibrillar structures similar to
those observed in other neurodegenerative diseases [46], see
Figure 2O. The progressive disappearance of the aforementioned
species was observed in all CD batches analysed, so this effect is
unlikely to be due to synthesis or sample variability. Figures 2 M,
2N and 2P shows TEM images with higher magnification of HR,
CD and PrP106–126 peptides respectively.
Thioflavine Assays Demonstrate that CD Peptide is not
Amyloidogenic
We analysed aliquots of 50 mg/ml of CD, HR, CD and PrP106–
126 peptides for the presence of amyloid fibrils at 0, 0.5, 1, 2, 4, 8,
12 and 24 hours after dissolution of the lyophilized state. ThT
emits residual fluorescence in a fibril-free solution. However, ThT
is able to bind amyloidal fibrils, showing a peak in fluorescence at
455/485 nm excitation/emission (see [47] for a review). In our
experiments, the fluorescence levels of the four peptides were
measured using a single ThT aliquot, and a blank sample from
each aliquot was also used to test residual fluorescence from free
ThT in each condition. For this reason, we can reject artefacts
attributed to ThT aliquot variability or conservation state.
Moreover, we can exclude solvent variability as neither DMSO
nor PBS showed significant blank fluorescence levels.
As shown in Figure 2Q, the HR peptide presented the highest
level of fluorescence emission at 8 hours post-dissolution (over
36106 fluorescence relative units). In maximal emission time the
HR peptide showed a 7.2 and 7.79 fold increase with respect to
the CD, CC and PrP106–126 peptides, respectively. After 24 hours,
this peak in fluorescence declined slightly to ,16106 units.
However, there were no qualitative differences between 0 and 48
hours in TEM analysis (see Figures 2A, 2E and 2I) that would
clearly explain the decrease in ThT. Between 0 and 8 hours,
numerous intermediate structures with enhanced ThT-binding
ability might be present in the sample. After 8 hours, the increase
in mature fibrils might account for the decrease in ThT binding as
also described for other peptides (e.g., Ab [48]). Indeed, Gold-
slbury and coworkers point the higher increase in ThT fluores-
cence during the Ab transition to form mature fibrils and show a
similar decline in the fluorescence signal upon prolonged
incubation of Ab fibrils, suggesting that aged mature fibrils of
this peptide react worse with ThT [48]. Since non-refracting
quartz cells with a self-agitation system were employed to avoid
fluorescence disturbance during ThT experiments, we can discard
unspecific peptide adsorption to the cell walls or peptide
precipitation to be responsible for this fluorescence decline. In
contrast to HR, CC, CD and PrP106–126 peptides showed similar
fluorescence to the blank sample in every emission measure.
Lastly, only a few differences were found between different batches
(#1, #2 and #3), as previously mentioned (see Material and
Figure 4. AFM analysis of DMPC membrane interaction with CD, HR and PrP106–126 peptides. Topographic images of control (A) and CD-
treated artificial DMPC bilayer (B). Images were captured in tapping mode using 10 mM Hepes pH 7.40; 150 mM NaCl imaging buffer. Z = 15 nm. C)
Topographic image of CD-treated bilayer obtained via tapping mode capture. Notice the appearance of small membrane disruptions (asterisk) and
the increasing phase discontinuities (arrows). D) High power view of the boxed region in C illustrating the presence of both membrane disruptions
and emerging phase discontinuities after CD treatment. E) High power view of HR-treated bilayer obtained via tapping mode capture as above.
Notice the absence of the small membrane disruptions observed with the CD peptide. F) Topographic image of PrP106–126 -treated bilayer obtained
via tapping mode capture using 24 hours resuspended peptide. Notice the appearance of membrane disruptions (asterisks) and phase discontinuities
(arrows) in the membrane. Scale bars are indicated in each AFM image.
doi:10.1371/journal.pone.0070881.g004
Figure 5. Effects of CC, HR, CD and PrP106–126 peptides on
leakage of SUVs. Histogram showing the percentage of leakage of
the vesicle (ANTS/DPX) of POPC or DMPC SUVs induced by the
treatment with the different peptides at 40 mM. Bars represent the
mean 6 SEM of three independent experiments (** p,0.01 CD vs CC,
HR and PrP106–126).
doi:10.1371/journal.pone.0070881.g005
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Methods). Results in Figure 2Q shows the average between the
three batches.
It is important to note the reported lack of ThT binding to
PrP106–126 oligomers [49], while non-fibrillar oligomers of Ab bind
ThT, suggesting differing amounts of cross-b structure or poor
accessibility to dye in the case of the PrP106–126 or CD peptides.
Taking into account the poor understanding of ThT binding
modes to amyloid fibrils, in a recent study M. Groenning
propounded a model in which a cavity structure in the aggregated
protein that may allow ThT to bind [50]. In fact, it has been
described that some amyloid proteins display distinct patterns of
fibrillation and ThT emission, that correlates with differences in
the secondary peptide structures and the abundance of aggregates
formed [51,52]. In addition, we cannot rule out that specific
conformation of formed fibrils (twisted versus non twisted fibrils,
e.g., Figure 2M and Figure 2L) may also play a role in the
observed results.
CD Induces Neuronal Degeneration
We analysed cell viability after treatment with all four peptides
using a quantitative measure of PI emission (see above for details).
Each experiment was replicated three times with the different
batches of peptides. The results indicate that only the CD peptide
is able to induce an increase in neuronal death when used at
40 mM (,10% and ,35% at 24 and 48 hours, respectively)
shortly after preparation (Figure 3A). When the CD peptide was
allowed to aggregate for 24 hours before adding it to the cell
cultures, no significant toxicity was observed (Figure 3B). These
results suggest that cytotoxicity might be exerted by the unstable
spherical species of the peptide detected by TEM (Figure 2C),
which disappear over time after resuspension (Figures 2G and 2K).
As expected from previous results (e.g., [19]), PrP106–126 showed
significant toxicity when aggregated for 24 h after dissolution
(Figure 3B), supporting the delayed appearance of toxic aggregat-
ed species in this peptide with time [53]. Lastly, we performed a
time course with different concentrations of the CD peptide for
different periods of incubation. The results showed that as low as
5 mM of CD peptide caused a 2-fold increase in cell death after 48
hours of treatment (Figure 3C). Higher concentrations induced
higher rates of cell death, increasing drastically when 80 mM were
applied (cell death rates: 20% and 80% at 24 and 48 hours,
respectively, Figure 3C), indicating that cell death cause by CD
peptide is dose-dependent. The results obtained in the PI
fluorescence experiments were corroborated by the increase in
cleaved caspase-3 detected by Western blotting after CD
treatment. In contrast, the CC, HR and PrP106–126 peptides
showed similar levels of cleaved caspase-3 to controls (both
untreated and buffer incubated) at 40 mM (see Figure 3D) and
80 mM respectively (data not shown).
In order to determine whether death induced by the CD
peptide was dependent on the expression of PrPC, cerebellar
granule neurons from wild-type and Prnp0/0 mice were treated
with 100 mM of each peptide for 48 hours. The expression of PrPC
was determined by Western blot (Figure S1). Wild-type neurons
treated with the CD peptide showed an increase in cleaved
caspase-3 staining with respect to solvent-treated or CC-, HR- and
PrP106–126-treated neurons. Similar staining was observed in Prnp
0/
0 neurons (Figure 3E). Subsequent quantification of caspase-3-
stained neurons revealed a significant increase in neuronal death
in the CD (,35% and ,40% in Prnp+/+ and Prnp0/0, respectively)
compared to the PBS treatment (,2.5% (Prnp+/+) and ,3.5%
(Prnp0/0); Figure S2). As shown in Figure 3E, PrPC-deficient
neurons seemed slightly more susceptible (although non-statisti-
cally significant) to peptide treatment than Prnp+/+ neurons. This
difference could be attribute to intrinsic neuronal Prnp0/0
sensitivity as described previously [54], rather than to modulation
of this death mechanism by PrPC.
CD Peptides Disrupt Lipid Bilayers
The interaction of several prion synthetic peptides with the
plasma membrane has recently been analysed using AFM and
other techniques (see e.g., PrP110–136 [55] or PrP106–126 [25,26]).
Our results indicate that the CD peptide is able to modify the
stability of DMPC membranes, as observed in tapping mode
scanning AFM analysis (Figure 4A–B, C–D). In contrast, the HR
(Figure 4E), CC and PrP106–126 (not shown) peptides were unable
to generate a similar disaggregation under the same conditions
(without incubation time before AFM observation). In addition,
parallel experiments showed that 24-hour-aggregated PrP106–126
was also able to induce DMPC membrane disorganization
(Figure 4F). AFM time course analysis, demonstrate that the
disaggregation process of CD peptide implies the formation of
several phase discontinuities in the DMPC bilayer with the
increasing presence of holes surrounding these phase discontinu-
Table 1. Reported properties of different synthetic prion peptides.
Peptide Amyloidogenic properties Toxicity Membrane interaction References
PrP82–146 No data No data Yes [78]
PrP89–106 Yes Yes No [27]
PrP105–132 Yes Yes Yes [79]
PrP106–126 Yes Yes Yes [13,19]
PrP112–126 Yes Yes No data [13]
PrP113–120 Yes No No data [13]
PrP113–134 Yes Yes No data [13]
PrP118–135 Yes Yes Yes [61,79,80]
PrP120–133 Yes Yes Yes [79,80]
PrP120–135 Yes Yes Yes [79,80]
PrP121–134 No No No data [13]
PrP127–147 Yes Yes No [13,27]
doi:10.1371/journal.pone.0070881.t001
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ities (Figures 4C–D). This process is progressive, leading to
complete disaggregation of the artificial membrane, and was
observed in all CD batches in continuous cantilever tapping
scanning of DMPC-treated lipid bilayers (Figure 4B). These results
reinforce those presented previously indicating the low level of
interaction between the HR region and the plasma membrane (see
Discussion). Furthermore, they also suggest that the observed
cytotoxic effects of CD might be associated with the formation of
transient structures that are able to interact with the membrane.
To further confirm the membrane perturbation induced by the
CD peptide, ANTS-DPX leakage experiments were performed
[45] (see also Materials and Methods for details). The results
obtained show that, in contrast to CC, HR or PrP106–126, the CD
peptide increases permeability of POPC and DMPC SUVs just
after dissolution (Figure 5). We observed a ,11 and ,9 fold
increase in leakage in POPC and DMPC SUVs respectively at
40 mM peptide concentration (Figure 5).
Discussion
Prion-mediated neurodegeneration requires the appearance of
the abnormal misfolded form of the PrPC within nervous tissue. In
recent years, our knowledge concerning prion pathology has
increased. We now know that the presence of prion aggregates
lacking the GPI-anchor in the neural parenchyma does not
exclusively condition the neurotoxic process, but GPI-anchored
PrPC is important in the amplification and spread of prion
infectivity (e.g., [28,56]). In fact, deletion experiments have shown
that residues 108–124 of PrPC participate in PrPSC formation [57].
Several in vitro and in vivo studies have analysed prion neurotoxicity
using peptides based on regions of its sequence mainly associated
with the most conserved region of the protein (around the CR
residues) (see [13,58] for reviews and Table 1). PrPC species
lacking the N-terminal hydrophobic palindrome of PrPC; PrP
(112-AGAAAAGA-119) or PrP (122D119) could not convert to the
pathogenic prion [11]; and pioneer studies found that peptides
containing residues 106–126 of the protein were neurotoxic ([12],
see also [13,58]). Following these findings, several studies have
addressed questions such as i) whether the fibrillar form of the
prion is the main form responsible for neurotoxicity (e.g.,
[23,57,59,60]); ii) whether the cytotoxic effects of some of the
peptide are mediated or enhanced by the endogenous cell
expression levels of PrPC (e.g., [21,22,61]) and iii) which part of
the PrPC region is responsible for peptide cytotoxicity (e.g., [46])
(see Table 1 for some examples). In the present study, we analysed
the fibrillar properties of several peptides mimicking the CD of the
PrPC. Although it is obvious that we cannot fully translate the
present results to the full prion, some conclusions can be drawn.
While fibrillar structures have long been considered the
principal pathogenic agent in prion disease and other neurode-
generative disorders, there is growing evidence that amyloid
oligomers or intermediate fibrillar structures are in fact the
cytotoxic form that disrupts cell membranes through the formation
of ion channels, pores or other protein–lipid complexes (reviewed
in [46]). Although not fully comparable, in a study using the
amyloid b (Ab) peptide, Zhang and coworkers reported the higher
neurotoxic action in vitro of non-fibrillar forms when compared
with fibrillar structures [62]. In addition, a mutated form of the Ab
peptide with reduced fibrillar/aggregative potential showed
increased toxicity [63]. Regarding the prion disease, a study of
human samples showed that an increase in PrP oligomers
correlated with disease severity in CJD [59]. In this scenario, we
propose that the high degree of toxicity of the central domain
peptide (CD) versus the other peptides assayed (Table 1) can be
attributed to its inability to form fibrils and the large number of
spherical oligomers observed shortly after resuspension. It is
important to note that cell death is dependent on peptide
concentration (see Figure 3) and time of aggregation, such that
when the CD was allowed to aggregate for 24 h, toxicity declined
due to the loss of toxic forms (see Figure 2).
Another example of a PrPC peptide with in vitro and in vivo
cytotoxic properties under non-fibrillar conditions is PrP118–135
[61]. Its properties are similar to those observed for the CD
peptide. PrP118–135 mediates apoptosis independently of PrP
C
expression [61]. Nevertheless, unlike the CD peptide, PrP118–
135 has the capacity to form fibrils under determinate physical
conditions without losing toxicity associated [61]. This is also the
case for PrP106–126, which shows cytotoxic properties despite the
capacity to form fibrils, possibly due to the mixture of non-fibrillar
oligomers and amyloid fibrils or another species (see Figure 2) in
the samples used (see also [49]). However, although conflicting
[64,65] another study reported that PrP106–126 was not cytotoxic
[18]. Several in vitro studies have shown the high dynamics and
reversibility in the equilibrium between monomer and protofibril
formation of other amyloid proteins (e.g., Ab [52]), and the
coexistence of different species due to polymorphic fibril assembly
pathways [66]. Regarding PrP106–126, the equilibrium between
monomers and soluble oligomers, with an enrichment in
secondary structures, is independent of concentration [34], but
the fibrillar forms increase with time in a progressive manner [53]
in parallel with the toxic intermediate structures. Taken together,
the different described effects of PrP106–126 could be attributed to
the particular experimental conditions in each study. In addition
the presence of different species in the commercially available
PrP106–126 with putatively different properties may also have had
an impact in these studies. However, it is important to note that
not all non-fibrillar aggregated species have toxic effects in cells
[67] (see Table 1) explaining the lack of toxicity of PrP106–126
immediately after resuspension despite the annular structures seen
in TEM images (Figure 2D, P) and points that distinct toxic
oligomeric and/or annular intermediates may exist during
amyloid formation [67,68]. In this scenario PrP106–126 and CD
peptide could present, at different aggregation times, distinct
fibrillation intermediates that may share similar mechanisms of
cytotoxicity, however the heterogeneous composition of interme-
diates of PrP106–126 at 24 h of aggregation increase the difficulty to
study the toxic species in the sample.
Another aspect to consider is the relation between PrPC
expression levels and PrP peptide neurotoxicity. In previous
studies, we found that the complete absence of PrPC does not
prevent death induced by high-dose exposure to aggregated
PrP106–126 [19]. However, it has been reported that [21] the
increased expression of PrPC in cultured cells increased PrP106–126
neurotoxicity [22]. In fact, the absence or presence of PrPC, results
in several changes in protein (e.g., [69]) or transcription levels
([70,71,72] which may pre-condition cultured cells to the effects of
the synthetic peptides. Nevertheless, PrPC is not required for the
neurotoxic effects of some of the peptides. Thus, although the
presence of PrPC leads to increased binding of mimetic peptides or
other amyloid proteins to the plasma membrane (e.g. [73] see also
[74]), our results using Prnp0/0 cells indicate that the presence of
PrPC is not mandatory for the neurotoxic effect. On the other
hand, our data do not allow us to rule out the possibility that the
increased presence of PrPC in the plasma membrane may increase
cell death by membrane alteration or other processes in the
presence of the peptides.
Several studies have found that some PrP-mimetic peptides (e.g.,
PrP106–126 amide) are able to disrupt the lipid bilayer in AFM
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experiments [45] in a Ca2+-dependent manner [75]. In our AFM
experiments a similar pattern of membrane disaggregation to that
reported by Zhong and coworkers for PrP106–126 amide was
observed only with the CD peptide (PrP95–133) and to some extent
with aggregated PrP106–126 (Figure 4). This data was also
corroborated by SUVs leakage experiments (Figure 5). These
results may also be consistent with a recent report by Sauve et al.
on PrP110–136 [55], in which resuspended PrP110–136 in water
showed features of an unfolded protein in NMR experiments, and
under physiological conditions had a higher affinity for dodecyl-
phosphocholine micelles, being incorporated into the micelle in a-
helical conformation [55]. Thus, the putative disaggregation of the
membrane may lead to increased oxidative stress in treated cells
and cell death (see [19]). On the other hand, the parallelism
between intermediates in fibril formation in neurodegenerative
diseases and pore-forming toxins (PFTs) (e.g., [33,76]) is well
documented, although the cellular processes involved still remain
unknown. For example, it has been proposed that the fibrillar
deposits are in fact a defence mechanism for sequestering deadly
intermediate structures (reviewed in [77]). Given the difficulty of
studying intermediate species in the fibrillar pathway due to their
transitory nature, we propose that the CD peptide provides a tool
with which to advance research on the physiological and
pathological role of prion proteins.
Supporting Information
Figure S1 PrPC expression in cultured cerebellar gran-
ule neurons (CGN). Western blot analysis with 6H4 anti-PrPC
antibody of Prnp0/0 and Prnp+/+ CGN cultures after 3 DIV. Note
the presence of the different PrPC bands in the wild type and its
absence from Prnp0/0 cells.
(TIF)
Figure S2 Quantification of micrographs showing CD-
induced apoptosis in neurons (see Figure 3E). Bars
represent the mean 6 SEM of three independent experiments (*
p,0.05).
(TIF)
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